Elvucitabine (ACH-126,443, or Beta-L-Fd4C)

2-page PDF Elvucitabine Information

Also known as ACH-126443, L-Fd4C or beta-L-Fd4C, elvucitabine is a NRTI currently under investigation for the treatment of HIV infection and chronic hepatitis B.

In addition to its anti-HIV effects, elvucitabine has potent anti-HBV activity in laboratory studies. A Phase I/II study of elvucitabine in patients with chronic HBV infection demonstrated acceptable pharmacokinetics and safety. Phase II studies of elvucitabine in HBV-infected patients are underway.

Experimental NRTI Elvucitabine Suppresses HIV as well as Lamivudine at 48 Weeks - 11/07/2008

Elvucitabine Monotherapy Demonstrates Antiviral Activity in 7-day Study - 10/10/2006

Pharmacology of Elvucitabine Enables Innovative Dosing Regimens 1/13/06